Shorter treatment for candidemia (yeast infection in the blood)
Part of Infections clinical trials.
This trial compares a shorter course of antifungal medicine to a longer one for people who have candidemia (a yeast infection in the blood). It looks at whether treating for a shorter time is just as safe and effective, which could mean fewer side effects and a quicker recovery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have a yeast infection in your blood (called candidemia) that is not complicated by infected spots in other parts of your body like your eyes, heart, or joints.
- Your fever is gone and a recent blood test shows the yeast is no longer in your blood.
- If you have a central line (a special IV), it has been removed.
- You are not pregnant or breastfeeding, and if you can get pregnant, you agree to use birth control.
- You are expected to have low white blood cell counts for no more than 7 days.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial compares two lengths of antifungal treatment for a bloodstream yeast infection that has not spread: 7 days versus the standard 14 days. The goal is to see if a shorter course works just as well with fewer side effects.
This trial tests whether a shorter course of the antifungal drug caspofungin (7 days instead of the usual 14) is just as effective for people with uncomplicated candidemia, a bloodstream infection caused by Candida yeast. If you've already had 7 days of caspofungin and your blood is clear of Candida, you might be able to stop treatment sooner.
This Phase 3 trial tests fosmanogepix to treat adults with candidemia (Candida in the bloodstream) and/or invasive candidiasis (a deep Candida infection). It looks at whether the medicine is effective and safe, and whether it helps the infection improve when doctors also manage the infection source.
This trial compares shorter vs longer treatment for children with an uncomplicated yeast (Candida) bloodstream infection once blood cultures are clear. It may help reduce medicine exposure while keeping the infection under control.
This study tests whether a shorter course of an antifungal drug (fluconazole) plus earlier HIV treatment is safe and works as well as the standard approach for people with HIV who have a low level of cryptococcal antigen in their blood. It aims to prevent a serious fungal infection from developing.
This trial studies two types of antifungal medicines (amphotericin B and azoles) to see which works better for people with invasive fungal disease. It aims to help doctors choose the safest and most effective treatment.
Hear when a new Candidemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.